DGCI Approves Anti-fungal Medicine For Covid-linked Black Fu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A Mumbai-based bio-pharmaceutical firm has received approval from India's drug regulatory authority to use an anti-fungal drug for the treatment of black fungus or Mucormycosis, which recently saw an uprise among the patients recovering from the Covid-19.

The firm, Bharat Serums and Vaccines Limited, has become the first company in India to receive approval from Drug Controller General of India (DCGI) to use anti-fungal medication -- Liposomal Amphotericin B or LAmB -- as a medical intervention in patients of Mucormycosis.

Lately, many hospitals in India have reported the emergence of Mucormycosis cases in Covid-19 recovered patients. The health experts said that the infection can turn aggressive within two days of its onset if not diagnosed on time and many times, the patients have to let go of the organ it infects.

Those on immune-suppressing medications or long-term steroid use are the most vulnerable to Mucormycosis which also includes the patients of Covid-19 as steroids are used frequently to manage cytokine storms in the patients. Vishwanath Swarup, COO, Bharat Serums & Vaccines (BSV), said that anti-fungal medication can prevent the patients suffering from black fungus from progressing the stage of surgery.

BSV is indigenously developing and manufacturing the formulation of Amphotericin B. BSV is the first Indian company to get the regulatory approval of Liposomal Amph esotericin B, he added. The treatment involves a combination of surgical removal of affected tissues and the use of antifungal therapy. The treatment is usually intravenous Liposomal Amphotericin B (LAmB) International clinical guidelines recommend LAmB in the management of various invasive fungal infections.

Source:
https://health.economictimes.indiatimes.com/news/pharma/dgci-approves-anti-fungal-medicine-for-covid-linked-black-fungus-treatment/81505689
1 share
Like
Comment
Share